Comparative Pharmacology
Head-to-head clinical analysis: ILOTYCIN versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOTYCIN versus PEDIAMYCIN 400.
ILOTYCIN vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking peptidyl transferase activity and preventing translocation of peptides.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Erythromycin base (Ilotycin): 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day. For IV: 15-20 mg/kg/day continuous infusion or divided every 6 hours.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours in adults, prolonged to 4-6 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-15% biliary/fecal elimination.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic